D. Stephens, B. Greenwood, and P. Brandtzaeg, Epidemic meningitis, meningococcaemia, and Neisseria meningitidis, The Lancet, vol.369, issue.9580, pp.2196-2210, 2007.
DOI : 10.1016/S0140-6736(07)61016-2

R. Borrow, G. Carlone, N. Rosenstein, M. Blake, I. Feavers et al., Neisseria meningitidis group B correlates of protection and assay standardization???International Meeting Report Emory University, Atlanta, Georgia, United States, 16???17 March 2005, Vaccine, vol.24, issue.24, pp.5093-5107, 2006.
DOI : 10.1016/j.vaccine.2006.03.091

J. Finne, D. Bitter-suermann, C. Goridis, and U. Finne, An IgG monoclonal antibody to group B meningococci cross reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues, J Immunol, vol.138, pp.4402-4407, 1987.

J. Finne, M. Leinomen, and P. Makela, ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis, The Lancet, vol.322, issue.8346, pp.355-357, 1983.
DOI : 10.1016/S0140-6736(83)90340-9

P. Oster, D. Lennon, J. O-'hallahan, K. Mulholland, S. Reid et al., MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strain, Vaccine, vol.23, issue.17-18, pp.2191-2196, 2005.
DOI : 10.1016/j.vaccine.2005.01.063

E. Wedege, K. Bolstad, A. Aase, T. Herstad, L. Mccallum et al., Functional and specific antibody responces in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol, pp.830-838, 2007.

V. Masignani, M. Comanducci, M. Giuliani, S. Bambini, J. Adu-bobie et al., Using Three Variants of the Lipoprotein GNA1870, The Journal of Experimental Medicine, vol.63, issue.6, pp.789-799, 2003.
DOI : 10.1128/IAI.70.8.4447-4461.2002

D. Serruto, T. Spadafina, L. Ciucchi, L. Lewis, S. Ram et al., Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans, Proceedings of the National Academy of Sciences, vol.107, issue.8, pp.3770-3775, 2010.
DOI : 10.1073/pnas.0915162107

A. Kimura, D. Toneatto, A. Kleinschmidt, H. Wang, and P. Dull, Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates, Clinical and Vaccine Immunology, vol.18, issue.3, pp.483-486, 2011.
DOI : 10.1128/CVI.00304-10

M. Ramsey, N. Andrews, E. Kaczsmarki, and E. Miller, Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England, The Lancet, vol.357, issue.9251, pp.195-196, 2001.
DOI : 10.1016/S0140-6736(00)03594-7

M. Snape and A. Pollard, Meningococcal polysaccharide???protein conjugate vaccines, The Lancet Infectious Diseases, vol.5, issue.1, pp.21-30, 2005.
DOI : 10.1016/S1473-3099(04)01251-4

R. Borrow, N. Andrews, D. Goldblatt, and E. Miller, Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection, Infection and Immunity, vol.69, issue.3, pp.1568-1573, 2001.
DOI : 10.1128/IAI.69.3.1568-1573.2001

N. Andrews, R. Borrow, and E. Miller, Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England, Clin Diagn Lab Immunol, vol.10, issue.5, pp.780-786, 2003.

I. Sakou, G. Tzanakaki, M. Tsolia, M. Sioumala, A. Barbouni et al., Investigation of serum bactericidal activity in childhood and adolescence 3???6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine, Vaccine, vol.27, issue.33, pp.274408-4411, 2009.
DOI : 10.1016/j.vaccine.2009.05.047

X. Bai and R. Borrow, Genetics shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine, Expert Rev Vaccines, vol.2010, issue.910, pp.1203-1217

C. Frasch, R. Borrow, and J. Donnelly, Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease, Vaccine, vol.27, issue.2, pp.112-116, 2009.
DOI : 10.1016/j.vaccine.2009.04.065

J. Donnelly, D. Medini, G. Boccadifuoco, A. Biolchi, J. Ward et al., Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines, Proceedings of the National Academy of Sciences, vol.107, issue.45, pp.19490-19495, 2010.
DOI : 10.1073/pnas.1013758107

N. Ruijne, R. Lea, J. O-'hallahan, P. Oster, and D. Martin, Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of Infants, Clinical and Vaccine Immunology, vol.13, issue.7, pp.797-801, 2006.
DOI : 10.1128/CVI.00038-06

D. Livorsi, E. Stenehjem, and D. Stephens, Virulence Factors of Gram-Negative Bacteria in Sepsis with a Focus on <i>Neisseria meningitidis</i>, Contrib Microbiol, vol.17, pp.31-47, 2011.
DOI : 10.1159/000324008

B. Plikaytis, M. Stella, G. Boccadifuoco, L. Detora, M. Agnusdei et al., Inter-laboratory standardization of the sandwich ELISA designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines, Clin Vaccine Immunol, vol.2012, issue.1910, pp.1609-1617

U. Vogel, M. Taha, J. Vazquez, J. Findlow, C. H. Stefanelli et al., Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, The Lancet Infectious Diseases, vol.13, issue.5, pp.416-425
DOI : 10.1016/S1473-3099(13)70006-9

J. Bettinger, D. Scheifele, S. Halperin, W. Vaudry, J. Fidlow et al., Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB), Vaccine, vol.32, issue.1, 2013.
DOI : 10.1016/j.vaccine.2013.03.063

R. Ecdc-surveillance, Surveillance of Bacterial invasive Diseases in Europe, 2008.

S. Clarke, M. Diggle, P. Mölling, M. Unemo, and P. Olcén, Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?, Vaccine, vol.21, issue.19-20, pp.19-202468, 2003.
DOI : 10.1016/S0264-410X(03)00033-1

P. Mölling, M. Unemo, A. Bäckman, and P. Olcén, Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases, APMIS, vol.44, issue.Pt 1, pp.509-516, 2000.
DOI : 10.1034/j.1600-0463.2000.01087-8509.x

J. Suker, I. Feavers, M. Achtman, G. Morelli, J. Wang et al., The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation, Molecular Microbiology, vol.167, issue.2, pp.253-265, 1994.
DOI : 10.1084/jem.175.1.227

M. Comanducci, S. Bambini, D. Caugant, M. Mora, B. Brunelli et al., NadA Diversity and Carriage in Neisseria meningitidis, Infection and Immunity, vol.72, issue.7, pp.4217-4223, 2004.
DOI : 10.1128/IAI.72.7.4217-4223.2004

S. Jacobsson, S. Thulin, P. Mölling, M. Unemo, M. Comanducci et al., Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens, Vaccine, vol.24, issue.12, pp.2161-2168, 2006.
DOI : 10.1016/j.vaccine.2005.11.006

J. Lucidarme, M. Comanducci, J. Findlow, S. Gray, E. Kaczmarski et al., Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine, Clinical and Vaccine Immunology, vol.17, issue.6, pp.919-929, 2008.
DOI : 10.1128/CVI.00027-10

S. Bambini, A. Muzzi, P. Olcen, R. Rappuoli, M. Pizza et al., Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus, Vaccine, vol.27, issue.21, pp.2794-2803, 2009.
DOI : 10.1016/j.vaccine.2009.02.098

D. Martin, N. Ruijne, L. Mccallum, J. O-'hallahan, and P. Oster, The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB, Clinical and Vaccine Immunology, vol.13, issue.4, pp.486-491, 2006.
DOI : 10.1128/CVI.13.4.486-491.2006

S. Yazdankhah, P. Kriz, G. Tzanakaki, J. Kremastinou, J. Kalmusova et al., Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway, Journal of Clinical Microbiology, vol.42, issue.11, pp.425146-5153, 2004.
DOI : 10.1128/JCM.42.11.5146-5153.2004

S. Yazdankhah, K. Kesanopoulos, G. Tzanakaki, J. Kremastinou, and D. Caugant, Variable-Number Tandem Repeat Analysis of Meningococcal Isolates Belonging to the Sequence Type 162 Complex, Journal of Clinical Microbiology, vol.43, issue.9, pp.4865-4867, 2005.
DOI : 10.1128/JCM.43.9.4865-4867.2005

G. Frosi, A. Biolchi, L. Sapio, M. Rigat, F. Gilchrist et al., Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage, Vaccine, vol.31, issue.43, pp.314968-4974
DOI : 10.1016/j.vaccine.2013.08.006

L. Fagnocchi, A. Biolchi, F. Ferlicca, G. Boccadifuoco, B. Brunelli et al., Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine, Infection and Immunity, vol.81, issue.2, pp.560-569, 2013.
DOI : 10.1128/IAI.01085-12